A phase 2, randomised, placebo-controlled clinical trial of blisibimod, an inhibitor of B cell activating factor, in patients with moderate-to-severe systemic lupus erythematosus, the PEARL-SC study
Year: 2014
Type: article
Study designs: Randomized Controlled Trial, Clinical Trial
Source: Annals of the Rheumatic Diseases
Authors: R A Furie, G Leon, M Thomas, M A Petri, A D Chu, C Hislop, R S Martin, M A Scheinberg
Language: English
Subfield: Rheumatology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2097165105
